Jonathan Chang
Stock Analyst at Leerink Partners
(0.58)
# 4,145
Out of 5,141 analysts
76
Total ratings
28.57%
Success rate
-21.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Upgrades: Outperform | $3 → $13 | $8.64 | +50.46% | 11 | Oct 20, 2025 | |
| ZLAB Zai Lab | Maintains: Outperform | $73 → $75 | $20.04 | +274.25% | 9 | Jun 30, 2025 | |
| GMAB Genmab | Upgrades: Outperform | $27 | $29.29 | -7.82% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $32.75 | +125.95% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $24.78 | -55.61% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $11.36 | +348.94% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $9.67 | +675.59% | 12 | Jan 10, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $5.37 | +831.10% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $101.83 | -70.54% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $1.71 | +603.81% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $10.06 | +158.45% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $8.46 | +230.97% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $11.41 | +364.50% | 7 | Aug 5, 2021 |
Replimune Group
Oct 20, 2025
Upgrades: Outperform
Price Target: $3 → $13
Current: $8.64
Upside: +50.46%
Zai Lab
Jun 30, 2025
Maintains: Outperform
Price Target: $73 → $75
Current: $20.04
Upside: +274.25%
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $29.29
Upside: -7.82%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $32.75
Upside: +125.95%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $24.78
Upside: -55.61%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $11.36
Upside: +348.94%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $9.67
Upside: +675.59%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $5.37
Upside: +831.10%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $101.83
Upside: -70.54%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $1.71
Upside: +603.81%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $10.06
Upside: +158.45%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $8.46
Upside: +230.97%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $11.41
Upside: +364.50%